Last reviewed · How we verify
Maxipime (CEFEPIME)
Cefepime is a cephalosporin antibacterial drug.
Maxipime (Cefepime) is a cephalosporin antibacterial drug developed by Hospira Inc and currently owned by Baxter Healthcare. It is a small molecule that targets various bacterial infections, including those caused by Klebsiella pneumoniae, E. coli, and Proteus. Maxipime is FDA-approved for several indications, including bacterial peritonitis, pneumonia, and urinary tract infections. The drug has a high bioavailability of 99% and a half-life of 1.9 hours. Maxipime is off-patent, with multiple generic manufacturers available.
At a glance
| Generic name | CEFEPIME |
|---|---|
| Sponsor | Baxter |
| Drug class | Cephalosporin Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1996 |
Mechanism of action
Cefepime is cephalosporin antibacterial drug [see Microbiology 12.4)].
Approved indications
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial peritonitis
- Bacterial pneumonia
- Bacterial urinary infection
- Complicated Bacteroides Peritonitis
- Complicated E. Coli Peritonitis
- Complicated Klebsiella Peritonitis
- Complicated Proteus UTI
- Complicated Streptococcus Peritonitis
- Complicated Urinary Tract Infections
- E. Coli Pyelonephritis
- Enterobacter Pneumonia
- Escherichia coli urinary tract infection
- Infection due to Pseudomonas aeruginosa
- Infection due to Staphylococcus aureus
- Infectious disease of abdomen
- Klebsiella Pyelonephritis
- Klebsiella cystitis
- Pneumococcal pneumonia
- Pneumonia due to Pseudomonas
Common side effects
- Positive Coombs test (without hemolysis)
- Rash
- Diarrhea
- Nausea
- Vomiting
- Pruritus
- Fever
- Headache
- Decreased phosphorus
- Increased ALT/SGPT
- Increased AST/SGOT
- Eosinophils
Key clinical trials
- Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) (PHASE4)
- IO Vancomycin Spine (PHASE2,PHASE3)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales (PHASE3)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- SYN-004 Safety and Tolerability in Allo-HCT Subjects (PHASE1,PHASE2)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maxipime CI brief — competitive landscape report
- Maxipime updates RSS · CI watch RSS
- Baxter portfolio CI